Search

Physical–cognitive stimulation has emerged as a promising strategy for improving the quality of life of patients with amyotrophic lateral sclerosis (ALS). This case study reports on the use of immersive virtual reality (IVR) as a tool for multisensory stimulation in a woman with ALS (76 years old; 11 years since diagnosis; stage 2). The program consisted of IVR stimulation sessions (three sessions per week for 12 weeks). The results showed that the implementation of the program was feasible and safe (no adverse symptoms on the Simulator Sickness Questionnaire), as well as easy to execute (>80% on the System Usability Scale). Additionally, the participant reported improvements in aspects related to her mental health (44% depression and 20% anxiety) and improvements in her quality of life, and she also maintained her values in her functional capacity. This study presents novel and important findings by demonstrating the feasibility of implementing physical–cognitive stimulation programs with IVR in a person with ALS, allowing for multisensory stimulation with commercially available hardware and software and the generation of benefits in their health-related quality of life and mental health. [ABSTRACT FROM AUTHOR]

Intense exercise can be neuromodulatory and neuroprotective against Parkinson's disease (PD). Indoor cycling is a good and safe option for this population, but some barriers (monotonous and repetitive environment, lack of monitoring, and an inability to compete with others) could limit its use. Immersive virtual reality (IVR) could be a possible solution to some of these drawbacks, increasing patient motivation and thus adherence to forced exercise programs using cycloergometers. A double-blind, randomized, controlled clinical trial was conducted to explore the feasibility and effects of the ReViPark program (high-intensity pedaling + IVR for 3 months with two sessions per week) on PD progression. In all, 52 people with PD were allocated to the ReViPark group (n = 30; 70.87 ± 6.67 years) and smart cycloergometer group (n = 22; 70.59 ± 6.67 years). This program was feasible, with no adverse effects (no significant Simulator Sickness Questionnaire symptoms and a low negative experience rating for the Game Experience Questionnaire (0.04/4)), no dropouts, high adherence, and good usability (System Usability Scale score of 82.90%). The ReViPark group showed significant improvements in functionality, quality of life, and disease progression as measured by their balance, gait and risk of falling (Timed Up and Go p = 0.028; Tinetti test p = 0.046), PDQ-39 scores (p = 0.035), and MDS-UPDRS scores (p = 0.001). This program is feasible and could lead to improvements in the functional parameters, quality of life, and symptomatology of the participants. [ABSTRACT FROM AUTHOR]